Skip to main content
. 2016 Jun 10;7(8):768–773. doi: 10.1021/acsmedchemlett.6b00149

Figure 5.

Figure 5

Compound 3 in anti-CD3 mouse model. (A) pS6RP levels (normalized to total S6RP) measured in spleens of compound treated as compared to disease vehicle group (p < 0.01 for 1 mg/kg of 3; p < 0.001 for 3 and 10 mg/kg of 3; one outlier removed in normal control and disease vehicle group). (B) Exposure response fit: pS6RP levels at terminal exposure. EC50 0.22 μM (95% CI 0.15 to 0.32 μM). (C) pAkt levels (normalized to total Akt) measured in spleens of compound treated as compared to disease vehicle group (p < 0.001 for 1, 3, and 10 mg/kg of 3). (D) Exposure response fit: pAkt levels at terminal exposure. EC50 0.055 μM (95% CI 0.048 to 0.065 μM). Legend: White, normal controls (n = 4). Black, anti-CD3 vehicle 5%DMSO/95% (10% kleptose) (n = 6). Gray, anti-CD3/3 (1, 3, or 10 mg/kg, of 3 PO) (n = 6).